Moderna, Inc.（MRNA）今日盘中大涨6.94%，引起了市场广泛关注。
消息面上，公司近期多重利好持续推动股价走高。6月25日，Moderna举办了科学日活动，首次披露了体内CAR-T项目mRNA-6007，计划针对B细胞介导的自身免疫疾病于明年进入临床，同时展示了肿瘤疫苗、癌症预防疫苗及AI研发平台等多条管线，市场对其向平台型生物药企估值切换的预期持续升温。此外，其季节性流感疫苗mRNA-1010此前获得了美国食品药品监督管理局（FDA）咨询委员会9-0的一致支持，最终审批决定预计在8月初做出。
受上述积极进展鼓舞，多家投行上调了Moderna的目标价，例如Piper Sandler将其目标价上调至77美元，杰富瑞上调至53美元，这进一步增强了投资者的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.